Campbell Alliance's New Suite Of Services Delivers Launch Excellence To Clients

The Launch Suite Builds on Pioneering Model That Has Delivered an Average of 45 Percent Improvement in Time to Market for Clients

NEW YORK – Campbell Alliance, the consulting arm of inVentiv Health, today announced the formation of the Campbell Alliance Launch Suite, an integrated offering designed to bring products to market primed for success.

As pharmaceutical companies face patent expiries and shrinking pipelines, product launches are a critical component for growth. With over 400 launches on the horizon in the next three years, it will be crucial for pharmaceutical companies to capture the full value from each launch.

More than a decade ago, Campbell Alliance pioneered the Launch Playbook®. This strategic planning process and project management tool has resulted in clients experiencing an average of 45 percent improvement in time to launch when compared to launches of similar drugs that went to market without using the Launch Playbook®. Campbell Alliance built on this best-in-class offering to create a comprehensive Launch Suite for clients preparing to commercialize a new product in the current complex, crowded and competitive healthcare marketplace.

"Biopharmaceutical companies know that to successfully launch a product in the new healthcare environment, they need to redefine how they commercialize assets," said Michael Griffith, Executive Vice President of inVentiv Health and President of the Commercial Division. "The Campbell Alliance Suite is one offering of our Contract Commercial Organization (CCO), an outsourcing model that realizes efficiencies to accelerate performance and delivery. We have seen that enhanced commercialization leads to enhanced value."

The Suite pairs strategic insights and tools, informed by planning launches for nearly 60 percent of new U.S. molecular entities and more than 500 global launch engagements. The scalable offering allows clients to tap into experts who have managed launches across a wide range of product types, geographic markets and therapeutic areas. The Suite, which is centered on a proprietary launch framework, includes:

  • Launch Strategy: Insights and business-driven global and market-level launch strategy, with a focus on therapeutic areas, as well as product categories (e.g., rare diseases, biosimilars and small footprint launches).
  • Launch Planning: Leveraging the Launch Playbook® process and upgraded project management platform, Campbell guides clients in developing global launch plans, assessing launch readiness and developing risk mitigation plans. The Web-based Launch Playbook® tool features a new dashboard section for improved project management, risk tracking and enhanced reporting.
  • Launch Management: Seamless launch execution, utilizing the right tools and methodologies to develop meaningful key performance indicators and diagnose progress.
  • Launch Excellence: Institutionalization of Launch Excellence within an organization by establishing the foundational launch elements for developing strategy, planning and management.

"With the strategic recommendations from our launch and subject matter experts, we help clients design and assess their overall launch strategy, track and gauge their progress to launch and achieve critical outcomes," said Rohit Sood, Head of Global Launch Excellence at Campbell Alliance. "Launches are a key milestone in the success of an asset, and we recognize that the scope of each launch varies by asset and market. We fully adapt our approach and solutions to each client's business objectives and organizational footprint."

For more information on Campbell Alliance's Launch Suite, visit

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health and an industry leader in biopharmaceutical consulting. The firm's clients include all of the world's top 20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into five Practice Areas – Commercial Excellence, Commercial Strategy, Market Access, Medical and Corporate Development – each of which offers a range of services to a critical area of the pharmaceutical and biotechnology industries. Each of our Practice Areas has a dedicated consulting team whose members are highly specialized and offer deep expertise in their chosen areas. From its 13 office locations, the firm serves clients throughout North America, Europe and Asia. For more information on Campbell Alliance, please visit

About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. Seamlessly integrating a Clinical Research Organization (CRO) and a Contract Commercial Organization (CCO), inVentiv offers clients innovative solutions at critical moments on the path from discovery to delivery of treatments worldwide. With more than 13,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health's clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and terminations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of any future acquisitions; the impact of any change in our current credit ratings or the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our debt instruments and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; the impact of impairment of goodwill and intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.